Odyssey Therapeutics (NASDAQ:ODTX) Stock Rating Upgraded by Zacks Research

Odyssey Therapeutics (NASDAQ:ODTX) was upgraded by Zacks Research to a “hold” rating in a research note issued to investors on Wednesday,Zacks.com reports.

ODTX has been the topic of a number of other reports. Cantor Fitzgerald initiated coverage on Odyssey Therapeutics in a research report on Tuesday. They issued an “overweight” rating on the stock. TD Cowen initiated coverage on Odyssey Therapeutics in a research report on Tuesday. They set a “buy” rating on the stock. Wall Street Zen upgraded Odyssey Therapeutics to a “hold” rating in a research note on Saturday, May 16th. Oppenheimer initiated coverage on Odyssey Therapeutics in a research note on Tuesday. They set an “outperform” rating and a $40.00 price objective on the stock. Finally, Wedbush initiated coverage on Odyssey Therapeutics in a research note on Tuesday. They set an “outperform” rating and a $30.00 price objective on the stock. Five analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat, Odyssey Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $32.00.

Odyssey Therapeutics Stock Up 1.9%

Shares of ODTX opened at $17.00 on Wednesday. Odyssey Therapeutics has a 52-week low of $15.35 and a 52-week high of $20.30.

Insider Activity

In other news, Director Nan (Ln) Li acquired 1,111,111 shares of Odyssey Therapeutics stock in a transaction that occurred on Monday, May 11th. The shares were purchased at an average cost of $18.00 per share, for a total transaction of $19,999,998.00. Following the completion of the purchase, the director directly owned 3,333,516 shares of the company’s stock, valued at $60,003,288. This trade represents a 50.00% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Shelley Chu bought 11,111 shares of the company’s stock in a transaction on Monday, May 11th. The stock was bought at an average cost of $18.00 per share, for a total transaction of $199,998.00. Following the completion of the transaction, the director directly owned 11,111 shares of the company’s stock, valued at $199,998. This trade represents a ∞ increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders purchased a total of 4,183,777 shares of company stock valued at $75,319,986 over the last three months.